BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32668495)

  • 21. Inhibition of MicroRNA miR-101-3p on prostate cancer progression by regulating Cullin 4B (CUL4B) and PI3K/AKT/mTOR signaling pathways.
    Gu Z; You Z; Yang Y; Ding R; Wang M; Pu J; Chen J
    Bioengineered; 2021 Dec; 12(1):4719-4735. PubMed ID: 34338146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostaglandin E2 receptor EP4 is involved in the cell growth and invasion of prostate cancer via the cAMP‑PKA/PI3K‑Akt signaling pathway.
    Xu S; Zhou W; Ge J; Zhang Z
    Mol Med Rep; 2018 Mar; 17(3):4702-4712. PubMed ID: 29328471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway.
    Vo BT; Morton D; Komaragiri S; Millena AC; Leath C; Khan SA
    Endocrinology; 2013 May; 154(5):1768-79. PubMed ID: 23515290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression.
    Henderson V; Smith B; Burton LJ; Randle D; Morris M; Odero-Marah VA
    Cell Adh Migr; 2015; 9(4):255-64. PubMed ID: 26207671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The PI3K/AKT pathway in the pathogenesis of prostate cancer.
    Chen H; Zhou L; Wu X; Li R; Wen J; Sha J; Wen X
    Front Biosci (Landmark Ed); 2016 Jun; 21(5):1084-91. PubMed ID: 27100493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells.
    Lee SO; Lou W; Nadiminty N; Lin X; Gao AC
    Prostate; 2005 Jul; 64(2):160-7. PubMed ID: 15678501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SIRT5 Directly Inhibits the PI3K/AKT Pathway in Prostate Cancer Cell Lines.
    Choi SY; Jeon JM; Na AY; Kwon OK; Bang IH; Ha YS; Bae EJ; Park BH; Lee EH; Kwon TG; Lee JN; Lee S
    Cancer Genomics Proteomics; 2022; 19(1):50-59. PubMed ID: 34949659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LncRNA LINC01305 silencing inhibits cell epithelial-mesenchymal transition in cervical cancer by inhibiting TNXB-mediated PI3K/Akt signalling pathway.
    Yan SP; Chu DX; Qiu HF; Xie Y; Wang CF; Zhang JY; Li WC; Guo RX
    J Cell Mol Med; 2019 Apr; 23(4):2656-2666. PubMed ID: 30697971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GCN5 inhibition prevents IL-6-induced prostate cancer metastases through PI3K/PTEN/Akt signaling by inactivating Egr-1.
    Shao G; Liu Y; Ma T; Zhang L; Yuan M; Zhao S
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30333255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression Levels of IL-17A, IL-17F, IL-17RA, and IL-17RC in Prostate Cancer with Taking into Account the Histological Grade according to Gleason Scale in Comparison to Benign Prostatic Hyperplasia: In Search of New Therapeutic Options.
    Janiczek M; Szylberg Ł; Antosik P; Kasperska A; Marszałek A
    J Immunol Res; 2020; 2020():4910595. PubMed ID: 32537467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long non-coding DANCR targets miR-185-5p to upregulate LIM and SH3 protein 1 promoting prostate cancer via the FAK/PI3K/AKT/GSK3β/snail pathway.
    Sun W; Zu S; Shao G; Wang W; Gong F
    J Gene Med; 2021 Jul; 23(7):e3344. PubMed ID: 33885171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FGF2 regulates proliferation, migration, and invasion of ECA109 cells through PI3K/Akt signalling pathway in vitro.
    Shi H; Xu J; Zhao R; Wu H; Gu L; Chen Y
    Cell Biol Int; 2016 May; 40(5):524-33. PubMed ID: 26833879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LINC00665 promotes the viability, migration and invasion of T cell acute lymphoblastic leukemia cells by targeting miR-101 via modulating PI3K/Akt pathway.
    Abuduer M; A EZG
    Tissue Cell; 2021 Aug; 71():101579. PubMed ID: 34171521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of M3 muscarinic receptor by acetylcholine promotes non-small cell lung cancer cell proliferation and invasion via EGFR/PI3K/AKT pathway.
    Xu R; Shang C; Zhao J; Han Y; Liu J; Chen K; Shi W
    Tumour Biol; 2015 Jun; 36(6):4091-100. PubMed ID: 25964092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-92a promotes proliferation and inhibits apoptosis of prostate cancer cells through the PTEN/Akt signaling pathway.
    Yanshen Z; Lifen Y; Xilian W; Zhong D; Huihong M
    Libyan J Med; 2021 Dec; 16(1):1971837. PubMed ID: 34431444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breviscapine suppresses the growth and metastasis of prostate cancer through regulating PAQR4-mediated PI3K/Akt pathway.
    Ye J; Gao M; Guo X; Zhang H; Jiang F
    Biomed Pharmacother; 2020 Jul; 127():110223. PubMed ID: 32413672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of microRNA-138 alleviates human coronary artery endothelial cell injury and inflammatory response by inhibiting the PI3K/Akt/eNOS pathway.
    Li JB; Wang HY; Yao Y; Sun QF; Liu ZH; Liu SQ; Zhuang JL; Wang YP; Liu HY
    J Cell Mol Med; 2017 Aug; 21(8):1482-1491. PubMed ID: 28371277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDT1 facilitates metastasis in prostate cancer and correlates with cell cycle regulation.
    Wang C; Che J; Jiang Y; Chen P; Bao G; Li C
    Cancer Biomark; 2022; 34(3):459-469. PubMed ID: 35253732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.